Table 1 Demographic and transplant patient characteristics.

From: Safety and efficacy of narsoplimab in pediatric and adult patients with transplant-associated thrombotic microangiopathy: a real-world experience

Variable

Overall (N = 20)

Adults (N = 13)

Pediatrics (N = 7)

Age (years), median (range)

26.5 (5–71)

40 (32–71)

13 (5–19)

Male, No. (%)

8 (49)

5 (38)

3 (43)

Time from HSCT to TA-TMA diagnosis, days (range)

85.5 (24–452)

89 (30–452)

78 (24–246)

Time from current TA-TMA diagnosis to day 1, days (range)

3.5 (0–52)

3 (0–14)

7 (0–52)

Cell source, No. (%)

   

 Bone marrow

5 (25)

0 (0)

5 (71)

 Peripheral blood

14 (70)

12 (92)

2 (29)

 Cord blood

1 (5)

1 (8)

0 (0)

Matched donor, No. (%)

   

 Matched related

5 (25)

0 (0)

5 (71)

 Matched unrelated

5 (25)

5 (38)

0 (0)

Mismatched donor, No. (%)

   

 Mismatched related

3 (15)

1 (8)

2 (29)

 Mismatched unrelated

7 (35)

7 (54)

0 (0)

ABO incompatibility, No. (%)

   

 Major

6 (30)

4 (31)

2 (29)

 Minor

3 (15)

3 (23)

0 (0)

 Bidirectional

1 (5)

1 (8)

0 (0)

 None

10 (50)

5 (38)

5 (71)

Conditioning regimen, No. (%)

   

 MAC

11 (55)

4 (31)

7 (100)

 RIC

9 (45)

9 (69)

0 (0)

GvHD prophylaxis regimen, No. (%)

   

 ATG, CSA, MTX

11 (55)

9 (69)

2 (29)

 CSA, MMF, PTCy

4 (20)

2 (15)

2 (29)

 ATG, FK, MTX

1 (5)

1 (8)

0

 ATG, MMF, CSA

1 (5)

1 (8)

0

 CSA, MMF, MTX

1 (5)

0

1 (14)

 CSA, MMF

1 (5)

0

1 (14)

 CSA, MTX

1 (5)

0

1 (14)

Disease status at the time of transplant, No. (%)

   

 Active disease

9 (45)

7 (54)

2 (29)

 CR1

6 (30)

4 (31)

2 (29)

 CR2 or more

5 (25)

2 (15)

3 (43)

Baselinea platelet count, ×109/L

   

 ≤20, No. (%)

13 (65)

7 (54)

6 (86)

 >20, No. (%)

7 (35)

6 (46)

1 (14)

Baseline hemoglobin, g/dL (range)

9.1 (7.7–12.3)

9.1 (7.8–11.2)

9.4 (7.7–12.3)

Baseline platelets, per microliter (range)

16,000 (13,000–62,000)

18,000 (10,000–41,000)

14,000 (3000–62,000)

Baseline LDH, U/L (range)

531 (237–1201)

495 (237–1201)

702 (460–1073)

Acute GvHD ≥ overall grade 2, No. (%)

17 (85)

11 (86)

6 (86)

Infection, No. (%)

15 (75)

8 (61)

7 (100)

  1. Values are presented as the number of patients with the corresponding percentage relative to the total (20 patients), adult (13 patients), and pediatric (7 patients) populations.
  2. LDH lactate dehydrogenase, MAC myeloablative conditioning regimen RIC reduced intensity conditioning regimen, CR complete remission, GvHD graft versus host disease, ATG anti-thymocyte globulin, CSA cyclosporine, MMF mycophenolate mofetil, FK tacrolimus, PTCy post-transplant cyclophosphamide, MTX Methotrexate.
  3. aBaseline: at time of TA-TMA diagnosis.
Back to article page